A Feasibility Study to Evaluate the Safety of the TheraSphere Glioblastoma (GBM) Device in Patients With Recurrent GBM

This trial tests a device called TheraSphere GBM, which delivers tiny radioactive beads directly into a recurrent glioblastoma (an aggressive brain tumor) to try to shrink or control it. It is a first-in-human safety study. **You may be eligible if...** - You are 18 or older with a confirmed glioblastoma diagnosis that has come back or continued to grow after standard treatment - Your tumor is measurable on MRI (between 1–5 cm) - You have already received surgery, combined radiation and chemotherapy (temozolomide) - You have a life expectancy of at least 12 weeks and reasonable health to undergo the procedure **You may NOT be eligible if...** - You have not had prior standard treatment for glioblastoma - Your tumor is too large or not measurable by MRI - You are not able to tolerate the procedure or follow-up requirements Talk to your doctor to see if this trial is right for you.